Days | Control mortality ± SE | Corrected efficacy ± SE | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Conidial suspensions at concentration (conidia/ml) | |||||||||||||||
1×105 | 1×106 | 1×107 | 1×108 | F ratio | |||||||||||
BGF14 | 3 | 8.32±1.64 | 19.16±2.03 | B* | b** | 18.89±2.10 | C | b | 22.30±3.75 | B | b | 58.38±3.08 | B | a | 45.828 |
5 | 15.17±2.01 | 24.01±2.24 | B | b | 29.39±4.10 | B | b | 28.63±3.49 | B | b | 62.05±3.60 | B | a | 26.181 | |
7 | 24.38±3.20 | 31.44±2.76 | A | c | 47.10±2.94 | A | b | 44.95±3.62 | A | b | 76.98±3.32 | A | a | 36.520 | |
F ratio | 6.854 | 20.433 | 10.413 | 8.699 | P ≤ 0.05 | ||||||||||
BCA32 | 3 | 11.67±1.43 | 24.44±4.77 | B* | c** | 40.72±3.95 | B | b | 48.21±4.99 | C | ab | 57.94±3.66 | B | a | 10.446 |
5 | 19.28±2.20 | 46.87±3.69 | A | b | 58.68±3.75 | A | a | 64.24±2.80 | B | a | 67.37±3.44 | B | a | 6.890 | |
7 | 28.81±0.98 | 54.89±3.27 | A | b | 63.06±1.95 | A | b | 81.09±4.10 | A | a | 87.27±2.76 | A | a | 23.556 | |
F ratio | 15.892 | 12.560 | 16.355 | 20.515 | P≤0.05 |